Sino Biopharmaceutical Limited: Breast Neoplasms trials

The registry lists 18 Breast Neoplasms studies with Sino Biopharmaceutical Limited as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 9Phase 2 8Phase 3 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer SubjectsRecruitingNCT07697443Phase 1/2
• A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast CancerNot yet recruitingNCT07393321Phase 3
• Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerRecruitingNCT07008976Phase 3
• A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerRecruitingNCT07003074Phase 3
• The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast CancerRecruitingNCT06452706Phase 2
• A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerRecruitingNCT06202261Phase 1/2
• A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast CancerRecruitingNCT06172322Phase 1
• Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerTerminatedNCT06851442Phase 1/2
• Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerActive, not recruitingNCT06702618Phase 2
• A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerActive, not recruitingNCT06561607Phase 3
• A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerActive, not recruitingNCT06198751Phase 2
• A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast CancerCompletedNCT06115902Phase 1
• Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancerActive, not recruitingNCT05780567Phase 3
• A Clinical Trial of TQB3909 Tablets in Patients With Breast CancerStatus unknownNCT05775575Phase 1/2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)Status unknownNCT04405505Phase 3
• A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerStatus unknownNCT04355520Phase 1/2
• A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)Status unknownNCT03855358Phase 1
• A Bioequivalence Study of Capecitabine TabletsCompletedNCT01846650Phase 1